undamentalytics Newsletter
Sign in

Strata Critical Medical, Inc. key statistics and ratios

In fiscal 2025, Strata Critical Medical, Inc. had return on equity of 16.5% and a net margin of 21.0%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Sept 20192020Sept 20202021Sept 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Net margin−34.7%−43.4%−79.3%−18.7%−24.9%−18.6%21.0%−8.8%
Return on equity−52.3%−63.9%−26.5%−9.6%−22.0%−12.0%16.5%−8.9%
Return on assets−3.9%−6.9%−22.2%−8.2%−18.1%−9.9%14.2%−7.6%
R&D as % of revenue2.4%3.7%3.3%3.8%2.1%2.2%——
SG&A as % of revenue—————34.6%30.9%22.8%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · September 30, 2026
What it owns · $329m
Short-term assets $125mLonger-term assets $204m
What it owes, and who funded it · $329m
Short-term liabilities $45mLonger-term liabilities $7mShareholders' equity $276m
  • Short-term assets cover short-term liabilities $125m of assets due within a year against $45m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $125m short-term assets against $7m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Strata Critical Medical, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

10 /100

Weak moat

How hard Strata Critical Medical's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -7.5% of total assets over 7 years.

  • Durability 10 / 20

    Operating margin has been a median -28.0%; its worst year was -47.7%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -22.5% of revenue.

  • Discipline 2 / 20

    The diluted share count rose 103.2% over five years; stock-based pay has been a median 8.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (15 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: DCGO vs SRTASRTA vs VMDDLHC vs SRTA

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Strata Critical Medical, Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Strata Critical Medical, Inc.